Investor Relations

Partnerships are integral to Harbour BioMed's strategy to build a fully integrated biopharmaceutical company.

  1. Aug 31, 2022

    2022 Interim Results Online Conference

  2. Apr 09, 2022

    HBM7022 Out-license to AstraZeneca

  3. Mar 25, 2022

    2021 Annual Results Online Conference

  4. Dec 08, 2021

    201 R&D Day

  5. Sep 14, 2021

    HBM4003 Phase I Data Readout